Answer extracted from the The Conference Room with Simon Lader podcast — listen to the full episode below.
How does leadership differ between academic research, startup founding, and established research institutions?
Scientists are trained to reduce uncertainty through data and hypotheses, while founders must navigate uncertainty as a constant reality. Dr. Sherry Zhang combines both skill sets to ask more audacious questions and build bigger ecosystems, applying scientific rigor to forecast health trajectories while remaining responsive to customer feedback and the complex, non-linear nature of real-world health journeys.
The scientist's approach versus the founder's mindset
In academia, leadership is anchored in hypothesis testing and peer validation. You design an experiment, collect data, reduce variables, and publish findings—each step builds on proven knowledge. This systematic approach creates confidence in decisions, but it can also slow innovation when real-world complexity demands speed.
Founding a startup inverts this model entirely. As a founder, you operate in perpetual ambiguity: your product may not exist yet, your market may shift weekly, and your team may change before you find product-market fit. Uncertainty becomes your default state, not a problem to solve first. You make decisions with 60% of the information, knowing you'll course-correct once you learn more from customers.
Zhang's experience bridges both worlds. When she founded Genopalate with a mission to help more than 170,000 customers make personalized nutrition decisions based on their DNA, she applied rigorous genomics knowledge from her PhD research at Marquette University while simultaneously learning to iterate fast based on market feedback. As she explains in the episode, her drive to "deliver world-class science and translate that into something useful and practical for everyday people" meant developing skills far beyond the laboratory.
Building ecosystems at Buck Institute
Now leading external strategy and partnerships at the Price Lab at Buck Institute for Research on Aging, Zhang demonstrates how hybrid leadership scales. Her current work applies scientific rigor to forecast individual health trajectories while building an AI-native platform that listens to customer needs and adapts to the messy reality of how people actually manage their health over time.
This isn't academia avoiding commercial reality, nor is it a startup sacrificing scientific integrity for speed. It's a deliberate fusion: the patience of peer review combined with the agility of startup iteration, the credibility of a PhD combined with the humility to learn from users. A point detailed in this podcast is that effective leaders across all three environments—academia, startups, and established research institutions—must ultimately ask the same question: How do I create value for the people I serve?
"This drive in me to deliver world-class science and translate that into something useful and practical for everyday people is so strong that I think that will motivate me to learn new skills, to meet new people, to get on stage that I'll be nervous for, and raise funding."
Sherry Zhang — Executive Director of External Strategy and Partnerships at Price Lab, Buck Institute for Research on Aging. Dr. Zhang is a first-generation immigrant scientist who arrived in the United States from China with three bags and $3,000. She earned her PhD in molecular biology from Marquette University in Wisconsin, conducted obesity genomics research at Medical College of Wisconsin (MCW) under Dr. Ahmed Kaseba (who coined the concept of metabolic syndrome), and founded Genopalate, a personalized nutrition company that has served more than 170,000 customers. She now leads AI-driven approaches to extending human lifespan and preventive health optimization.
If you want to hear more about how Zhang navigated the specific challenges of building a biotech company from zero—from visa rejections to running Genopalate while working as faculty at MCW to managing investor relationships—the full conversation on Listenly covers her complete founder journey and the lessons that shaped her leadership across all three environments.
Key takeaways
- Academic leaders reduce uncertainty through data; startup founders accept uncertainty as permanent and make decisions with incomplete information.
- The hybrid approach—combining scientific rigor with startup agility—enables leaders to ask bolder questions and scale impact faster.
- Translating science into practical value requires learning skills beyond your original discipline: marketing, fundraising, customer feedback loops, and rapid iteration.
- Established research institutions benefit most when they adopt startup-like responsiveness to real-world complexity while maintaining scientific credibility.
See also
What are the core mistakes first-time biotech founders make in team building and partnerships?
First-time founders must surround themselves with people who share their dream and align with their principles and values. Building a team of trusted collaborators who understand your mission is essential, even if they disagree on execution details.
How should biotech founders approach fundraising and investor relationships?
Trust building and finding aligned investors are critical. Rather than accepting funding too quickly, founders should conduct numerous conversations and test relationships carefully to ensure investor and company values align.
What drives a scientist to transition from academic research into founding a biotech company?
Dr. Sherry Zhang identified defining moments where her genomics research—particularly FTO gene variants and weight loss outcomes—revealed an opportunity to help people apply scientific knowledge practically to improve their lives.